Adding Immunotherapy to Neoadjuvant Chemo Boosts pCR in HR-Positive Breast Cancer
(MedPage Today) -- SAN ANTONIO -- Adding an immune checkpoint inhibitor (ICI) to chemotherapy significantly increased the rate of pathologic complete response (pCR) and reduced residual cancer burden (RCB) in high-risk early-stage hormone receptor...
Source: MedPage Today OB/GYN - Category: OBGYN Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Hormones | Immunotherapy | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | OBGYN